Reliance on third-party contractors for installation and service
Poor service quality or delays can damage product performance, compliance, and customer trust.
- Scope
- Healthcare and commercial installations
- Materiality
- high
Nephros, Inc
Nephros, Inc. develops and sells water filtration and ultrafiltration products used in healthcare and commercial settings. Its systems are designed to improve water quality and help reduce infection and contamination risks in hospitals, dialysis centers, and foodservice or hospitality facilities.
6,8 %
61,9 %
6,4 %
+32,7 %
4.06
2.89
| % | |
|---|---|
| Healthcare water filtration | 55% Ultrafilters and related products used in hospitals and medical facilities to reduce waterborne pathogens. |
| Dialysis water treatment | 15% Filtration products used in dialysis centers and dialysis equipment to remove biological contaminants. |
| Commercial water filtration | 25% Filters sold into foodservice, hospitality, convenience store, and industrial applications. |
| Services and support | 5% Installation, servicing, maintenance, and technical support for deployed systems. |
Nephros sells to hospitals, dialysis providers, and other healthcare facilities that need water filtration for...
- Hospitals and other healthcare facilitiesprimary
Buy ultrafilters for infection control, patient safety, and waterborne pathogen reduction.
- Dialysis centers and dialysis equipment usersprimary
Buy filtration products for hemodialysis water and bicarbonate concentrate treatment.
- Commercial foodservice and hospitalityprimary
Buy water filters for ice machines, beverage systems, and drinking water quality.
- Convenience stores and restaurantssecondary
Buy filtration products to improve water taste, odor, and equipment performance.
- Distributors and service partnerssecondary
Buy and resell products or provide installation and service to end customers.
Nephros is a U.S.-based company with corporate headquarters, research, manufacturing, and distribution facilities in...
- •Headquartered in the United States, with facilities in New Jersey
- •Primary operations include research, manufacturing, and distribution in New Jersey
- •Commercial growth depends on distribution partners in target markets
- •Service coverage must be built locally for installation and maintenance
- •No country-level revenue split was disclosed in the excerpts
Nephros is focused on growing sales of its water filtration products while controlling operating costs and preserving...
01
Expand commercial distributionshort-term
Commercial growth now depends on new partners after the Donastar relationship ended.
02
Maintain and grow healthcare adoptionmedium-term
Hospitals and dialysis centers are core end markets for the ultrafiltration platform.
03
Improve operating cash flowshort-term
The company wants to fund operations internally and reduce financing dependence.
Nephros depends on third-party contractors and distributors to install, service, and sell its products, so execution...
Dependence on new distribution partners in commercial markets
After the Donastar termination, commercial sales growth depends on partner execution.
- Scope
- Food, beverage, and hospitality markets
- Materiality
- high
Regulatory compliance and FDA oversight
Medical-use products are subject to testing, labeling, distribution, and approval rules.
- Scope
- Ultrafilters used in healthcare settings
- Materiality
- high
Supply-chain dependence on third-party product suppliers
The company is vulnerable to supply disruptions and price fluctuations.
- Scope
- Product sourcing and inventory availability
- Materiality
- medium
Demand volatility in emergency-response sales
Management noted elevated emergency-response sales may not persist.
- Scope
- Quarterly revenue mix
- Materiality
- medium
Point-in-time revenue recognition
Quarterly revenue and margin volatility
Variable consideration estimates
Net revenue and gross margin
Inventory reserves and write-offs
Gross profit and operating income
Goodwill and intangible asset impairment
Non-cash charges to earnings
Stock-based compensation
Operating expense and net income
: 28.4.2026